On November 12, 2019 Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, reported that it will be presenting new data supporting its methylation-based liver cancer diagnostic test at The Liver Meeting 2019 hosted by the American Association for the Study of Liver Diseases (AASLD), taking place in Boston from Nov. 8-12 (Press release, Laboratory for Advanced Medicine, NOV 12, 2019, View Source [SID1234551011]). AASLD selected Laboratory for Advanced Medicine’s data for poster presentation as a "Poster of Distinction." Posters of Distinction are classified as being in the top 10% of scored poster abstracts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data from the presentation, titled "A DNA Methylation-Based Diagnostic Platform: Towards Early Detection of Hepatocellular Carcinoma," suggests that using the DNA methylation panel for hepatocellular carcinoma (HCC) provides superior performance than the current standard of care screening methods such as ultrasound and alpha-fetoprotein. This analysis evaluated blood samples from 450 subjects by using DNA methylation technology which correctly detected HCC in patients for an overall sensitivity of 88% (n= 218/249) and correctly identified 96% of healthy donors (n= 80/83) and 98% of patients with benign disease (n=116/118) with a combined specificity of 97%.

"These results highlight the importance of continued development and validation of blood-based DNA methylation biomarkers for detecting liver cancer early," said Dhruvajyoti Roy, PhD, Director of Technology at LAM. "The new results and continued validations strongly support Laboratory for Advanced Medicine’s ongoing clinical trial to evaluate the performance of the liver cancer test for the detection of HCC within a high risk population."

AASLD Poster Presentation Details:

Abstract Number: 0843

Abstract Title: "A DNA METHYLATION-BASED DIAGNOSTIC PLATFORM: TOWARDS EARLY DETECTION OF HEPATOCELLULAR CARCINOMA"

Location: Hynes Convention Center, Hall B

Poster Session Date: Saturday, November 9, 2019

Poster Session Time: 2:00 PM – 7:00 PM

On November 12, 2019 AbbVie Inc. (NYSE:ABBV) ("AbbVie") reported that it has priced its previously announced private offering (the "Offering") of senior unsecured notes in a combined aggregate principal amount of $30 billion (collectively, the "Notes") (Press release, AbbVie, NOV 12, 2019, View Source [SID1234551010]). The Notes will be issued in ten tranches: (i) $750,000,000 in aggregate principal amount of senior floating rate notes due May 2021, (ii) $750,000,000 in aggregate principal amount of senior floating rate notes due November 2021, (iii) $750,000,000 in aggregate principal amount of senior floating rate notes due 2022, (iv) $1,750,000,000 in aggregate principal amount of 2.150% senior notes due 2021, (v) $3,000,000,000 in aggregate principal amount of 2.300% senior notes due 2022, (vi) $3,750,000,000 in aggregate principal amount of 2.600% senior notes due 2024, (vii) $4,000,000,000 in aggregate principal amount of 2.950% senior notes due 2026, (viii) $5,500,000,000 in aggregate principal amount of 3.200% senior notes due 2029, (ix) $4,000,000,000 in aggregate principal amount of 4.050% senior notes due 2039 and (x) $5,750,000,000 in aggregate principal amount of 4.250% senior notes due 2049. AbbVie expects that the closing of the Offering will occur on November 21, 2019, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Offering is being conducted in connection with AbbVie’s previously announced acquisition (the "Acquisition") of Allergan plc ("Allergan"). AbbVie expects to use the net proceeds from the Offering to fund a portion of the aggregate cash consideration due to Allergan shareholders in connection with the Acquisition and to pay related fees and expenses, with any remaining net proceeds being used for general corporate purposes. The Offering is not conditioned upon the consummation of the Acquisition. However, if (i) the Acquisition has not been consummated on or prior to January 30, 2021 or (ii) prior to such date, AbbVie notifies the trustee in respect of the Notes that it will not pursue the consummation of the Acquisition, then AbbVie will be required to redeem all of the Notes then outstanding at a special mandatory redemption price equal to 101% of the aggregate principal amount of the Notes, plus accrued and unpaid interest, if any, to, but not including, the applicable special mandatory redemption date.

The Notes have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), any state securities laws or the securities laws of any other jurisdiction, and may not be offered or sold in the United States, or for the benefit of U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities or blue sky laws. Accordingly, the Notes are being offered in the United States only to persons reasonably believed to be "qualified institutional buyers," as that term is defined under Rule 144A of the Securities Act, or outside the United States to non-"U.S. persons" in accordance with Regulation S under the Securities Act.

A confidential offering memorandum for the Offering of the Notes has been made available to such eligible persons. The Offering is being conducted in accordance with the terms and subject to the conditions set forth in such confidential offering memorandum.

This news release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, the Notes or any other security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation or sale would be unlawful.

On November 12, 2019 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported the launch of Personalis’ Cancer Whole Genome Sequencing which further extends Personalis’ portfolio of comprehensive cancer genomics services designed to maximize biological insights from tumor samples (Press release, Personalis, NOV 12, 2019, View Source [SID1234551009]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This new offering continues our push to provide our customers genomics solutions that enable deeper insights into patient responses to oncology therapies," said John West, CEO of Personalis. "We are uniquely poised to provide a leading cancer whole genome sequencing solution which combines Personalis’ deep technology and experience in analyzing cancer samples for biopharma oncology clinical trials and the large-scale laboratory and data systems developed for the VA MVP program, one of the largest whole genome sequencing programs in the world."

Earlier this year, Personalis was awarded a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA Million Veteran Program (VA MVP). This order brought the cumulative scale of orders received to date from the VA MVP to over 110,000 human genomes. Since 2013, Personalis has sequenced over 40,000 MVP samples. Personalis anticipates it will sequence the additional samples over the coming years as they are received from the VA.

"As our understanding of the complexity of underlying mechanisms of cancer grows, it is becoming increasingly important to evaluate genome-wide structural variants, and other forms of non-coding genetic variation," commented Dr. Richard Chen, CSO of Personalis. "This new service advances our position at the leading edge of cancer translational research with biopharma customers."

On November 12, 2019 Exelixis, Inc. (Nasdaq: EXEL) reported that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the Stifel 2019 Healthcare Conference being held next week in New York (Press release, Exelixis, NOV 12, 2019, View Source [SID1234551008]). Exelixis’ presentation has been scheduled for Tuesday, November 19, 2019 at 9:10 AM EST / 6:10 AM PST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.

On November 12, 2019 Baystate Health, the premier integrated health system serving more than 800,000 patients in western New England, reported a strategic partnership with Life Image, the largest medical evidence network providing access to points of care and curated clinical and imaging data, to develop novel artificial intelligence tools that would help advance technical innovations in radiology, neurology and oncology (Press release, Baystate Health, NOV 12, 2019, View Source [SID1234551007]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Specifically, TechSpring, the innovation arm for Baystate, will work closely with Life Image to evaluate a number of AI solutions including those that promise to improve speed and accuracy in diagnosing blood clots in stroke patients; improve clinical pathways for physicians treating or diagnosing a patient by finding and comparing clinical criteria against a group of de-identified patients with similar clinical characteristics; and identify potential patient matches to oncology clinical trials in order to advance cancer research as well as give western New England residents better access to potentially life-saving treatments.

Baystate and Life Image began working together 10 years ago when the health system became one of the company’s first customers. Life Image created the image exchange category when it developed solutions more than a decade ago to help solve the many technical and structural barriers that prevented the seamless exchange of medical images.

With its beginnings in image exchange, Life Image is now a global medical evidence network that offers ‘living’ datasets of novel imaging data that’s linkable to other clinical information and provides network access to points-of-care to enable improved care delivery, novel research and innovation.

Baystate has been a healthcare innovator since 1873 when it first established the modern American hospital in Springfield, which was one of only 178 acute care hospitals in the country. Baystate has played an important role in the evolution of the healthcare industry by advancing leading-edge methods such as fast-track cardiac, chronic care, homeopathic medicine and educational innovation for physicians and nurses.

"Baystate Health and TechSpring are excited to partner with Life Image on the next generation of healthcare technology with AI initiatives that have targeted use cases with high clinical utility and value," said Richard Hicks, MD, Department Chair of Radiology at Baystate. "For example, by understanding how similar patients may have been diagnosed or treated can help improve accuracy and, ultimately, patient outcomes."

Baystate launched TechSpring five years ago to accelerate innovation in healthcare informatics and technology in order to solve the challenges of healthcare. TechSpring provides technology companies access to a real, live health system using a proven process and platform to test and validate digital health solutions.

"TechSpring has tackled a variety of challenges for Baystate, from transitions in care to operational efficiencies. This is a big, bold next step into the world of AI," said Joel Vengco, Vice President, Chief Information Officer and TechSpring Founder. "Baystate is a living lab to pursue those big ideas, learn quickly and eventually share with the wider market."

"Life Image enables creative collaborations outside of healthcare’s traditional silos through use of its leading technical capabilities and unmatched evidence-based network," said Matthew A. Michela, President and CEO of Life Image. "This partnership with Baystate and TechSpring will facilitate new breakthrough technologies that work in the real healthcare world, specifically in the practice setting where patients and clinicians interact."

Accenture analyzed key clinical health AI applications and found that they can potentially create $150 billion in annual savings in the United States by 2026. A McKinsey report found that a potential for healthcare AI to deliver between $350 billion and $410 billion in annual value by 2025.